SNDK’s −8.5% Move Looks Like an Overreaction

I see no supplied earnings or estimate deterioration that explains today’s −8.5% move, so on these data it looks like an overreaction, not a change in my view. Q3 revenue rose 377.9% year over year to $11,031M, and free cash flow reached $6,309M; consensus still sees FY2027 EPS of $227.481 and FY2028 EPS of $289.054. At $857.53, that is 3.8x and 3.0x those respective estimates. But I remain cautious as a cyclical investor: the 73.4% Q3 net margin may not be sustainable, and EPS swung from losses in FY2023–FY2025 to $73.760 in FY2026. The price is already down 52.0% over three months. I hold my one share: the fall alone is no reason to sell, but peak-cycle risk keeps me from adding.